Pooled data from 14,489 patients found estimated sensitivity of PSA for prostate cancer was 0.93 (95% CI 0.88, 0.96) and specificity was 0.20 (95% CI 0.12, 0.33). The area under the hierarchical summary receiver operator characteristic curve was 0.72 (95% CI 0.68, 0.76). Bumps or growths can indicate the presence of prostate cancer. Along with a PSA test, a doctor can help confirm a prostate cancer diagnosis by feeling for growths or tumors through the rectum What is the ExoDx™ Prostate Test? The ExoDx™ Prostate Test is a simple, non-DRE, urine-based, liquid biopsy test indicated for men 50 years of age and older with a prostate-specific antigen (PSA) 2-10ng/mL, or PSA in the "gray zone", considering an initial biopsy. The ExoDx Prostate test returns a risk score that determines a patient's risk of clinically significant prostate cancer Prostate Cancer and Prostatic Diseases - Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test the sensitivity of the test was 96.3 The standard PSA test measures the amount of free and bound PSA in the blood. Screening. There is no national screening programme for prostate cancer in the UK. This is because previous research showed that the PSA test isn't a reliable test that can pick up prostate cancer that needs treatment. Research is going on to find a new test. A simple blood test, phi provides better prostate cancer detection to reduce negative biopsies. The FDA-approved test combines PSA, free PSA and p2PSA tests. Prostate Health Index results are based on a score that provides information on the probability of finding prostate cancer and providing confidence in biopsy decisions. .

sensitivity of psa test for prostate cancer